PROVECTUS PHARMA
PVCT
0.81 USD
-0.03
-3.571%
As of 3:59:29 PM on 5/1/2012. All times are ET. Market data is delayed by at least 15 minutes.
Exchange:
OTCBB
Sector:
HEALTHCARE
Industry:
Drug Manufacturers - Major
Claim site

Snapshot

Open: 0.87 Day's Range: 0.81 - 0.87 Volume: 140,040 Bid: 0.65 Ask: 1
Previous Close: 0.84 52wk Range: 0.67 - 1.23 Market Capitalization: N/A Bid Size: 25 Ask Size: 25

Latest Posts

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) Announces Positive Test Results
Thursday, April 5, 2012 10:15 AM EST
Provectus Pharmaceuticals recently presented results that show how its cancer drug PV-10 works.Read More

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) Moving Forward With Cancer Drug Testing
Thursday, February 2, 2012 11:28 AM EST
Provectus Pharmaceuticals continues moving towards a Phase 3 trial of a drug that could be used in the treatment of melanoma. Read More
All Posts

Latest News

Phase 2 Data on Provectus’s PV-10 to Be Presented at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on April 13, 2012
Tuesday, April 10, 2012
Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 study of PV-10 for metastatic melanoma will be presented at the HemOnc Today -- Melanoma and Cutaneous Malignancies Conference on April 13, 2012. Professor Merrick Ross, M.D.   Read More

Intralesional PV-10 Treatment Leads to the Induction of Anti-Tumor Immunity
Monday, March 26, 2012
--Results Detailed at the Society of Surgical Oncology Annual Meeting Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that nonclinical data on the immunologic mechanism of action of PV-10, presented at the 2012 Society of Surgical Oncology Annual Me   Read More

Mechanism of Action Data On PV-10 Demonstrates Therapy Induces Immunologic Response
Friday, March 23, 2012
--- Results Detailed in Poster Presentation at the Society of Surgical Oncology Annual Meeting; Details of Poster Expected to Be Released Next Week - Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that nonclinical data on the immunologic mechanism of action   Read More
see more...

Stock Chart

chart
Copyright © 2012 GLX.com. All rights reserved. Powered by
About | Advertising | Privacy | Terms | Help |